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What’s the evidence that NICE guidance has been implemented?
Results from a national evaluation using time series analysis, audit
of patients’ notes, and interviews
Trevor A Sheldon, Nicky Cullum, Diane Dawson, Annette Lankshear, Karin Lowson, Ian Watt, Peter West,
Dianne Wright, John Wright
Abstract
Objectives To assess the extent and pattern of implementation
of guidance issued by the National Institute for Clinical
Excellence (NICE).
Design Interrupted time series analysis, review of case notes,
survey, and interviews.
Setting Acute and primary care trusts in England and Wales.
Participants All primary care prescribing, hospital pharmacies;
a random sample of 20 acute trusts, 17 mental health trusts,
and 21 primary care trusts; and senior clinicians and managers
from five acute trusts.
Main outcome measures Rates of prescribing and use of
procedures and medical devices relative to evidence based
guidance.
Results 6308 usable patient audit forms were returned.
Implementation of NICE guidance varied by trust and by topic.
Prescribing of some taxanes for cancer (P < 0.002) and orlistat
for obesity (P < 0.001) significantly increased in line with
guidance. Prescribing of drugs for Alzheimer’s disease and
prophylactic extraction of wisdom teeth showed trends
consistent with, but not obviously a consequence of, the
guidance. Prescribing practice often did not accord with the
details of the guidance. No change was apparent in the use of
hearing aids, hip prostheses, implantable cardioverter
defibrillators, laparoscopic hernia repair, and laparoscopic
colorectal cancer surgery after NICE guidance had been issued.
Conclusions Implementation of NICE guidance has been
variable. Guidance seems more likely to be adopted when there
is strong professional support, a stable and convincing evidence
base, and no increased or unfunded costs, in organisations that
have established good systems for tracking guidance
implementation and where the professionals involved are not
isolated. Guidance needs to be clear and reflect the clinical
context.
Introduction
The National Institute for Clinical Excellence (NICE), established
in 1999 by the Department of Health, aims to improve standards
of care for patients and reduce inequalities in access to
innovative treatments.1 NICE’s technology appraisals result in
guidance on the use of individual health technologies; around 50
for implementation by the NHS in England and Wales since
2000.2 Hitherto, guidance on treatments was uncoordinated.
This nationally coordinated programme of guidance is probably
unique and represents a policy embodiment of evidence based
medicine that, it is hoped, will lead to the rapid and systematic
uptake of evidence based medicine into routine practice. This
paper presents the results of a national evaluation examining the
pattern of implementation of NICE guidance by healthcare
organisations.More details on NICE and a copy of the full report
can be accessed via www.nice.org.uk.
Methods
We assessed the response of the NHS to 12 pieces of “tracer”
NICE guidance. We selected guidance for study if at least six
months had elapsed since its release. By the time the research
began in October 2001, 22 sets of guidance were eligible for
inclusion (table 1): four procedures (four selected), five devices
(three selected), one diagnostic test, and 11 pharmaceutical
drugs (five selected). We audited 11 (50%) of the eligible sets of
guidance, chosen to reflect a range of drugs, devices, and proce-
dures; different care settings; and cost consequences. Some
included clear stopping messages (wisdom teeth, laparoscopic
surgery for colorectal cancer); some fairly clear messages to use
a technology (implantable cardioverter defibrillators, hearing
aids); and other complex messages regarding appropriate use
(hip prostheses, taxanes for breast cancer, orlistat).
The research consisted of three phases, each one using a dif-
ferent method of data collection to answer different but comple-
mentary questions.
Phase I
We analysed routine national or regional data and national sur-
veys (centrally collected data; box 1) to assess the extent to which
practice changed after publication of the tracer guidance. We
used data from the NHS Prescription Pricing Authority, which
covers all of England, to explore trends in the primary care pre-
scribing of relevant drugs. We used hospital episode statistics
data (covering England and Wales) to assess the trends in use of
invasive procedures. We accessed or directly collected a range of
other sources of national and regional data where these two
sources did not have relevant or adequate data (box 1). Table 2
shows data sources used for each of the 12 sets of guidance.
We used interrupted time series analysis to assess if the pat-
tern of practice had changed after NICE guidance3 and so infer
whether the intervention had an impact. We used an autoregres-
The interview schedule for clinicians is on bmj.com
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sive integrated moving average (ARIMA) model with dummy
variables to examine the impact of publication on the growth
rate and the average rate of use (constant parameter) of a
technology once any growth rate had been removed.4
Phase II
Most NICE guidance provides criteria for appropriate use rather
than a simple recommendation to use the technology or not. To
assess whether the guidance was being implemented properly
requires scrutiny of patient records by using methods developed
for appropriateness studies.5 6 We selected a random sample of
20 (out of 221) acute trusts and their associated mental health
hospitals and 21 (out of 303) primary care trusts (within which
we selected a stratified random sample of five practices), from
which we reviewed 50 relevant case notes for each of eight guid-
ance topics (table 2). The resulting trusts reflected a good cross
selection of geographical spread and size.
Local audit staff agreed to extract data from patients’ records
by using audit proforma. Overall usable audit forms for 6308
patients were returned (table 3). We calculated the proportion of
cases conforming to the NICE guidance for each healthcare
organisation in the sample at two periods of time and estimated
the overall average.
Phase III
We surveyed the chief executives, leads of clinical governance,
and leads of clinical specialties of the 20 acute trusts that partici-
pated in the audit of patients’ notes (65% response rate for chief
executive officers (13 out of 20) and 57% overall (68 out of 120))
to assess their handling of NICE guidance. We also conducted
semistructured interviews to access professional and managerial
perspectives on our quantitative findings and, in particular, to
explore the response to the NICE guidance.
We purposively selected five acute trusts7 that returned posi-
tive consent forms, to represent differing degrees of implemen-
tation of guidance (see phase II). In each trust we approached the
chief executive, medical director, and lead clinicians for the guid-
ance topic. We supplemented a common interview schedule (see
appendix on bmj.com) by specific interview questions based on
findings from the audit. We offered all interviewees face to face
interviews but finally conducted three interviews by telephone.
Where possible we recorded and transcribed interviews. Where
recording proved impossible we returned notes to the
interviewee for checking.
Data analysis was concurrent, and clear thematic categories
and subcategories emerged.8 9 Two researchers working inde-
pendently developed these categories and compared and recon-
ciled differences by discussion. We used analytic matrices to
examine differences between trusts and across sets of guidance.10
Results
Wisdom teeth extraction
National data indicate a sharp decline in the number of
extractions between 1995 and 2001 (fig 1). Although these fell in
the year in which the guidance had been published (in March
2000), we found no evidence of a change in the downward trend
Table 1 NICE guidance sampling for audit
Title Completed Selected
Procedure Wisdom teeth—removal (No 1) Apr 2000 Yes
Device Hips—prostheses for primary total hip replacement (No 2) Mar 2000 Yes
Pharma Ovarian cancer—taxanes (No 3) May 2000 Yes
Device Drug eluting stents (No 4)—obsolete, replaced by No 71 May 2000 No
Diagnostic Cervical smear tests—liquid based cytology (No 5)—obsolete, replaced by No 69 Jun 2000 No
Pharma Breast cancer—taxanes (No 6) Jun 2000 Yes
Pharma Dyspepsia—proton pump inhibitors (No 7) Jul 2000 No
Device Hearing disability—new advances in hearing aid technology (No 8)—obsolete, withdrawn Jul 2000 Yes
Pharma Diabetes (type 2)—rosiglitazone (No 9)—replaced by No 63 Aug 2000 No
Device Asthma—inhalers for children under five (No 10) Aug 2000 No
Device Arrhythmias—implantable cardioverter defibrillators (No 11) Sep 2000 Yes
Pharma Glycoprotein IIb/IIIa inhibitor guidance for acute coronary syndromes (No 12)—obsolete, replaced by 47 Sep 2000 No
Pharma Attention deficit hyperactivity disorder (ADHD)—methylphenidate (No 13) Oct 2000 No
Pharma Hepatitis C—interferon alfa and ribavirin (No 14) Oct 2000 No
Pharma Flu—zanamivir (Relenza) (No 15)—obsolete, replaced by 58 Nov 2000 Yes
Procedure Knee joints (defective)—autologous cartilage transplantation (No 16) Dec 2000 No
Procedure Colorectal cancer—laparoscopic surgery (No 17) Dec 2000 Yes
Procedure Hernia (inguinal)—laparoscopic surgery (No 18) Jan 2001 Yes
Pharma Alzheimer’s disease—donepezil, rivastigmine, and galantamine (No 19) Jan 2001 Yes
Pharma Motor neurone disease—riluzole (No 20) Jan 2001 No
Pharma Diabetes (type 2)—pioglitazone (No 21)—replaced by No 63 Mar 2001 No
Pharma Obesity—orlistat (No 22) (last eligible guidance) Mar 2001 Yes
Box 1: Other sources of centrally collected data
• Dental Practice Board and the Scottish Practitioner Services
data for national information on extractions of wisdom teeth in
the community
• Trent Arthroplasty Audit Group and Welsh Arthroplasty Audit
Group Database (TWAAG) for information on prostheses used
in hip replacement. This register of knee and hip replacements
covers the former NHS Trent Region and the North Wales
region contained the records of 7898 patients who had received
hip replacements since January 1998 in 22 hospitals (accounting
for 40% of the hip replacements undertaken in these hospitals)
• British Pacing and Electro-physiology Group ICD Register for
information on implantable cardioverter defibrillators for
arrhythmias. The data, submitted to the register by hospital
clinicians, covered the period from the first quarter of 1995 (33
centres) to the last quarter of 2001 (58 centres) and represents
about 95% of activity
• A new survey of hearing aid provision sent to all 228 audiology
departments in England and Wales (50% response rate)
• A new survey of all 331 hospital pharmacies in England and
Wales (68% response rate and 60% with usable data)
Papers
page 2 of 8 BMJ VOLUME 329 30 OCTOBER 2004 bmj.com
 on 12 November 2004 bmj.comDownloaded from 
in extractions ( − 8.9 extractions per month, 95% confidence
interval − 57.5 to 39.6). Case note review showed that more than
90% of extractions were compliant with the guidance. Survey
respondents indicated that compliance was high because the
costs of implementation were low, involved a single specialty
service, and had professional support and a strong evidence
base.
Hip prostheses
The guidance recommended the use of prostheses with a
demonstrable replacement rate of 10% or less, at 10 years, or a
minimum of three years, provided that the performance of the
prostheses is consistent with the 10 year benchmark. The
guidance did not specify which prostheses met the benchmark
Table 2 Overview of the 12 sets of guidance selected as “tracer” guidance, research questions, and data sources
Guidance (date of
publication)
Health technology
(health sector) Summary of NICE guidance Research questions Centrally collected data
Locally collected
data
Removal of wisdom teeth
(March 2000)
Procedure (hospitals
and general dental
practitioners)
The routine practice of prophylactic
removal of pathology free, impacted third
molars should be discontinued in the NHS
The surgical removal of impacted third
molars should be limited to patients with
evidence of pathology
Has there been a reduction in the number
of wisdom teeth removed in situations
where there are no apparent
complications?
Hospital episode
statistics (HES)
Dental Practice Board
and the Scottish
Practitioner Services data
Patient audits
Survey
Interviews
Prostheses for hip
replacement (April 2000)
Procedure (hospitals
and NHS Purchasing
and Supply Agency)
Surgeons should use prostheses for total
hip replacement that either have a
demonstrable replacement rate of 10% or
less at 10 years, or a minimum of three
years provided that their performance is
consistent with the 10 year benchmark
Are approved prostheses used in
replacement operations?
Are the numbers of approved prostheses
rising and of non-approved prostheses
falling?
Hospital episode
statistics (HES)
Trent Arthroplasty Audit
Group and Welsh
Arthroplasty Audit Group
Database (TWAAG)
Patient audits
Survey
Interviews
Taxanes for treatment of
breast cancer (May 2000)
Drugs (hospitals) Paclitaxel and docetaxel should be used
for advanced cancer when previous
chemotherapy has failed
Has the use of paclitaxel and docetaxel
increased to NICE recommended levels?
Hospital pharmacy
survey
Patient audits
Survey
Interviews
Taxanes for ovarian cancer
(June 2000)
Drugs (hospitals) Paclitaxel should be used after surgery Has the use of paclitaxel increased to
NICE recommended levels?
Hospital pharmacy
survey
Patient audits
Survey
Interviews
Hearing aids (July 2000) Devices (audiology
centres and NHS
Purchasing and
Supply Agency)
The full range of analogue hearing aids in
the current NHS range should be available
at all NHS audiology centres, including
binaural fitting, and reflecting patients’
choice
The NHS Purchasing and Supply Agency
should review the existing NHS range of
analogue aids
Has there been a change in the availability
of analogue hearing aids in NHS
audiology centres?
Has the NHS Purchasing and Supply
Agency reviewed the NHS range of
analogue hearing aids?
A new survey of hearing
aid provision sent to 228
audiology departments in
England and Wales.
Patient audits
Survey
Interviews
Implantable cardioverter
defibrillators for
arrhythmias (September
2000)
Devices (hospitals) The use of implantable cardioverter
defibrillators for patients with specific
pathologies should be routinely
considered
Has there been an increase in the use of
implantable cardioverter defibrillators to
NICE recommended levels?
British Pacing and
Electro-physiology Group
ICD database
None collected
Zanamivir for influenza
(November 2000)
Drugs (primary care) Zanamivir should be prescribed only to
adults at risk, who have presented within
36 hours of the onset of influenza-like
illness, when influenza is circulating in the
community
Has there been in an increase in the
prescribing levels of zanamivir
concomitant with increases of the
presence of influenza-like illness in the
community?
Prescribing data from
Prescription Pricing
Authority
Annual flu levels from
Public Health Laboratory
Service bulletins
None collected
Laparoscopic surgery for the
treatment of colorectal
cancer (December 2000)
Procedure
(hospitals)
Open rather than laparoscopic resection
should be the preferred procedure for the
treatment of colorectal cancer
Laparoscopic surgery should be
undertaken for colorectal cancer only as
part of a randomised controlled clinical
trial
Is laparoscopic surgery being undertaken
on patients with colorectal cancer outside
clinical trials?
Hospital episode
statistics (HES)
None collected
Laparoscopic surgery for the
treatment of inguinal hernia
(January 2000)
Procedure
(hospitals)
Open (mesh) surgery should be the
preferred method of repair for primary
inguinal hernia
Laparoscopic surgery should be
considered for repair of recurrent and
bilateral inguinal hernia
Has there been an increase in the number
of laparoscopic repairs for patients with
recurrent and bilateral inguinal hernia, and
a reduction for those with primary
inguinal hernia?
Hospital episode
statistics (HES)
Patient audits
Survey
Interviews
Donepezil, rivastigmine, and
galantamine for Alzheimer’s
disease (January 2001)
Drugs (hospitals and
primary care)
The three drugs should be made available
to people with mild and moderate
Alzheimer’s diseases, with scores in the
mini-mental state examination above 12
points as assessed in specialised clinics
Has the use of the three drugs increased? Prescribing analysis and
cost (PACT) data
Hospital pharmacy
survey
Patient audits
Survey
Orlistat for obesity
(March 2001)
Drugs (hospitals and
primary care)
Orlistat should be made available only to
people who have sustained weight loss
before prescription and a body mass
index of 30 kg/m2 or more with no
comorbidities or 28kg/m2 or more with
comorbidities
Has the use of orlistat increased? Prescribing analysis and
cost (PACT) data
Hospital pharmacy
survey
Patient audits
Chemotherapy for non-small
cell lung cancer (June
2001)
Drugs (hospitals) Gemcitabine, paclitaxel, and vinorelbine
should each be considered as part of
initial (first line) chemotherapy. Docetaxel
should be used for locally advanced
cancer but only where previous
chemotherapy has failed
Has the use of the four drugs increased? Hospital pharmacy
survey
None collected
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and the NHS Purchasing and Supply Agency was slow to issue
this information (which was subsequently withdrawn).
Use of more than 50 different prostheses was documented in
the Trent and Wales register over the period 1998-2002. Of the
single prostheses, 69% (3671) met the 10 year benchmark and
81% (4327) met the three year benchmark, proportions that had
been declining over recent years. There is some evidence that the
decline in 10 year benchmarked prostheses may have stabilised
slightly after guidance (1.7 monthly increase after guidance (95%
confidence interval 0.4 to 3.1) compared with a long term
monthly decrease of − 1.8 prostheses per month ( − 0.75 to
− 2.80)). We observed similar results from the audit of patients’
notes: 66% (325), 74% (727), and 75% (734) of heads, cups, and
stems, respectively, meeting the benchmarks. Interviews and the
survey indicated that surgeons thought that the guidance did not
acknowledge the complexity of hip surgery, and some surgeons
interviewed believed that cementless prostheses would ulti-
mately prove to offer longer service.
Taxanes for breast and ovarian cancer
We obtained usable data on taxanes from 24 hospital
pharmacies (including nine cancer centres). We found a
significant increase in the use of docetaxel and paclitaxel of 1112
(95% confidence interval 530 to 2222, P < 0.001) patient months
and 3.7 (1.1 to 7.8, P < 0.002) patient months, respectively (fig 2),
but no evidence of a change in the growth rate in the use of
gemcitabine (0.5% per month, − 36.2% to 37.2%) or vinorelbine
( − 1.0 patient months, − 3.3 to1.3). This is unlikely to be due to
lack of statistical power.
Case note review showed that, of the 707 patients identified
as receiving taxanes for breast cancer, all but one were receiving
this appropriately (for more advanced forms of the disease or in
the context of randomised controlled trials). Interviewees
acknowledged that the NICE guidance had made funding easier
to obtain. The picture for ovarian cancer, however, was more var-
ied. Of the 520 women with ovarian cancer for whom we have
data, only 33% (166) were recorded as having been prescribed
Table 3 Response from audit of patient case notes with reasons for failure to complete
Guidance No of trusts participating
No of individual completed
audit forms returned No used Reasons for non-return
Wisdom teeth 18 892 836 Service provided by primary care trust
Hip replacement 20 990 980 All returned
Breast cancer 17 708 707 Clinicians in two trusts declined to
participate. One trust did not complete as not
a cancer centre
Ovarian cancer 16 521 520 Clinicians in two trusts declined to
participate. One trust did not complete as not
a cancer centre
Hearing aid technology 18 875 875 One service provided by primary care trusts;
one trust declined to participate as pilot site
for digital aids
Inguinal hernia 19 950 938 One trust did not return—no reason given
Drugs for Alzheimer’s disease (mental health
trusts)
17 703 583 One participating trust did not return—no
reason given
Drugs for Alzheimer’s disease (primary care
trusts)
18 215 180 Three trusts did not return forms—no reason
given
Orlistat in primary care 18 689 689 Three trusts did not return—no reason given
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paclitaxel. However, oncologists interviewed believed that the
guidance had overstated the effectiveness of taxanes in ovarian
cancer. NICE subsequently amended its guidance.
Implantable cardioverter defibrillators
Although the number of implantable cardioverter defibrillators
implanted has risen, we found no evidence of a significant
change after NICE guidance had been published (fig 3). Given
the small data set, the power is low to detect a change as signifi-
cant, but visual inspection does not indicate any structural break.
This may reflect the high costs of implantable cardioverter defi-
brillators, at around £20 000 ($36 000; €29 ) per device, compe-
tition for resources with other interventional procedures in
cardiology, and scarcity of skills in electrophysiology.11
Hearing aids
The NICE guidance seems to have been received enthusiastically
by audiology departments; all of those surveyed had undertaken
an immediate audit of their service against the guidance require-
ments. However, review of case notes indicates that the range of
analogue hearing aids offered does not seem to have been
extended. Funding was described in the interviews as a major
impediment to implementation. The guidance was issued at the
same time as the Department of Health implemented a series of
pilots of digital hearing aids, which cut across the guidance on
analogue aids, which was subsequently withdrawn.
Laparoscopic surgery for primary inguinal hernia repair
and colorectal cancer
Only 4% of primary inguinal hernia repairs in England and
Wales were undertaken laparoscopically (contrary to NICE guid-
ance), and this did not change after the guidance (0.3 monthly
increase in hernia repairs, 95% confidence interval − 5.48 to
6.08).
Although hospital episode statistics data for the 19 trusts that
returned audit forms also showed 96% compliance, our audit of
545 repairs of primary unilateral hernias indicated only 65%
compliance, indicating that coding of hospital episode statistics
data may be unreliable. However, both national and audit data
agreed that most laparoscopic procedures were concentrated in
a few trusts, and that did not change over time.
Interviews showed that some local expert surgeons had the
support of managers and commissioners to continue the use of
laparoscopic surgery for primary repair. It was also claimed that
patients often requested laparoscopic procedures.
The percentage of cases of colorectal cancer treated with
laparoscopic surgery remained unchanged, at around 0.1% from
1998 to 2001.
Zanamivir for influenza
National prescribing data show little inappropriate prescribing
of zanamivir in the absence of high levels of flu; prescriptions
remained very low, at 499 in 2001, 190 in 2002, and 124 in 2003.
Orlistat for obesity
We found a significant increase in the average monthly prescrib-
ing of orlistat after the guidance had been published 22 per
month (0.43, 95% confidence interval 15.9 to 27.8, P < 0.001; fig
4). Health authorities increased their use of orlistat, standardised
by age, in the year after NICE guidance had been issued by about
eight patient months per 1000 people aged 18-75 years. The
variation in use, as measured by the coefficient of variation, fell
from 0.4 in 2000-1 to 0.3 in 2001-2.
In the 689 primary care patients for whom we have a record
we found evidence that the drug was not being prescribed in
accordance with guidance. Only in 12% of cases (n = 83) were
there data showing compliance in the three key areas of age,
body mass index, and weight loss. However, data recording was
poor, and data were missing in one or more fields in 80% (551)
of returns, particularly in respect of weight and weight loss. In
those 308 cases where patients’ weight loss prior to the visit had
been recorded fully, the weight loss criterion was not met in 40%
(123) of cases. Of patients with recorded weight loss data, only
41% (127) and 25% (40) still being prescribed orlistat at 3
months and 6 months, respectively, had reduced their weight as
advised in the NICE guidance. The rise in prescribing of orlistat
therefore does not necessarily imply a rise in appropriate
prescribing.
Drugs for Alzheimer’s disease
Total use grew logarithmically since February 1999 (fig 5). Once
this had been taken into account, the growth rate at the time of
publication of guidance ( − 1.4% per month; 95% confidence
interval − 4% to 1.2%) did not increase significantly. However,
the data are also compatible with a view that an increase in trend
occurred shortly before the guidance was formally issued.
Variability between health authorities decreased; the coefficient
of variation fell from 1.1 to 0.97.
Based on the audit data from 583 usable forms, compliance
with the five recommendations in the guidance at first prescrip-
tion varies between 52% and 85% for mental health
organisations and 21% and 46% in primary care. Compliance
with the recommendations at follow up is low, mainly because
information regarding mini-mental state examination scores,
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follow ups, or the presence of relatives at assessment was not
routinely recorded (a requirement of the guidance).
Discussion
Principal findings
The evidence that NICE guidance has made a difference either
to the quality of care or to variations in practice is mixed. Some
NICE guidance has been associated in time with changes in pre-
scribing. Use of orlistat and taxanes grew rapidly after NICE
guidance had been published, and uptake of drugs to treat
Alzheimer’s disease also increased, although this slightly
preceded the release of that guidance. The guidance for wisdom
teeth was published during a long downward trend in the extrac-
tion rate and did not have a discernable additional effect. The
guidance for hips in general showed no effect. We found no evi-
dence of a change in the number of implantable cardioverter
defibrillators used, the numbers of inguinal hernias or colorectal
cancers treated laparoscopically, or expansion in the range of
hearing aids made available. In some cases audit showed that
clinical practice was highly compliant with the indications for
treatment laid out in the guidance (for example, wisdom teeth
and the use of taxanes for breast cancer), but compliance was low
for some (such as orlistat) and more variable for others. Some
trusts seemed to exhibit more consistent compliance than others
across a range of guidance, and box 2 shows their characteristics,
although all identified funding as a major issue, especially where
infrastructure costs were high.
Strengths and weaknesses of the study
In a retrospective observational study we cannot fully assess the
impact of NICE guidance because of the absence of the counter-
factual and because NICE guidance is just one, although poten-
tially important, factor influencing professional practice. We can
only observe whether clinical practice is consistent with the guid-
ance. This research was based on a large data gathering exercise,
and although data taken from national routine hospital and pri-
mary care are complete, those obtained from hospital
pharmacies were less so. Where data were recorded, the audits
allowed us to assess more reliably whether the details of practice
corresponded to the indications of appropriateness in the guid-
ance compared with subjective surveys12 and analyses based sim-
ply on routine data.13 It was, however, sometimes difficult to
design audits where the original wording of the NICE guidance
had been complex or ambiguous. This is also likely to affect the
ease with which the guidance is implemented. Our survey also
offered a view of the management context into which the guid-
ance was received, and the interviews were useful in highlighting
the managerial, financial, and clinical perspectives on implemen-
tation.
Meaning of the study
The establishment of NICE as a mechanism for institutionalising
evidence based health care was a unique initiative. This
institutional response by itself is, however, not sufficient for the
rapid and universal implementation of evidence based health
care. This is unsurprising; NICE guidance is being issued at a
time of great change in the NHS, with new structures, competing
high level priorities, funding deficits, and staff shortages. In addi-
tion, healthcare organisations are complex, containing strong
professional bureaucracies.14 Change is therefore heavily
dependent on the actions of groups of professionals and
individual clinicians.15 The ability to manage change in an
organisation is further complicated by the increasing impor-
tance of networks that span several organisations.
The diffusion of innovations literature indicates that the
adoption of guidance would depend on several other factors
(box 3; after Rogers).16 17 These also emerged in the thematic
analysis of the interview data (table 4). In areas where practition-
ers and managers see advantages to adoption, where the value is
hardly disputed (clear evidence), and where there is professional
endorsement (taxanes for breast cancer, wisdom teeth extrac-
tion, and orlistat for obesity) practice has changed relatively fast.
The marketing activity of the pharmaceutical industry should
not be overlooked as a possible explanation for the apparent
increased uptake of drugs over devices and changes in surgical
behaviour.
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Box 2: Features of trusts consistent with high compliance
• Commitment to managing process of implementing guidance
• Identification of lead clinician at point of NICE announcement
of topic for review
• Proactive assessment of local costs and implications of
implementation
• Responsibility for funding and implementation vested in
locality-wide group
• Strong clinical governance function appropriately resourced
• Culture of consensus
• Recognition of legitimacy of NICE
• Involvement of clinicians in guideline process
• Financial stability
• Expectation that compliance is mandatory, subject to
identification of funding
• Targeted audit of areas of non-compliance
Box 3: Factors influencing adoption of innovation (after
Rogers16)
• Perceived attributes and consequences of adoption (for
example, relative advantage, complexity, observability)
• Type of innovation decision (optional, collective authority)
• Communication channels (for example, media, interpersonal,
professional)
• Nature of the social system (norms, degree of
interconnectedness of networks, concentration of opinion
leaders)
• Extent of promotion efforts by agents of change
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If the evidence has been disputed, or the costs not covered by
increased income, adoption is more variable. Where practice is
complex and also depends on an interaction with a practitioner’s
skills (such as with hip replacements or laparoscopic surgery),
more formative research to understand the clinical context of
practice may have helped to produce more influential guidance.
Adoption may also be influenced by the degree to which
decisions rest with an individual or requires team or
organisational agreement. Individual surgeons are likely to have
a high degree of professional autonomy, and this may partly
explain the variability in techniques for hernia repair and hip
replacement.
The extent to which trusts are prepared for NICE guidance
and have put in place structures and processes to manage their
implementation was variable.
The degree of active promotion by NICE is likely to have
some impact on adoption, although probably not directly
proportional to the effort invested. The greatest effect is likely
when opinion leaders including the professional bodies and
associations adopt and promote the guidance.
Table 4 Analysis of interviews: factors influencing likelihood of implementation
Theme Subtheme
Positive tendency towards implementation Negative tendency towards implementation
Influencing factors Illustrative quotes Influencing factors Illustrative quotes
Trust culture Committed to implementing NICE
guidance
“Locally NICE advice is seen to be
binding . . . .”
Not viewed as priority
No implementation pressure
from centre
“The clinician in me says that NICE is
actually important because it’s about
the treatment and care the patient
gets. The pressures in the service
from the centre are about finance and
waiting lists; they’re not about NICE.”
Locality decisions Structures Responsibility for NICE guidance
vested in health community
“The management of NICE guidance is
not just a trust affair—it is managed
within the whole health economy. We
have a NICE implementation group,
chaired by a primary care trust public
health director.”
Left to individual clinicians “Here, it has traditionally been left to
individual clinicians.”
Priorities Topic high on priority list “As an economy we are signed up to
NICE, but the politics are of priorities
and choice. By and large NICE
outweighs other issues.”
Topic low on priority list “There are lots of such initiatives in
the NHS—trust managers were
supportive in principle but just
couldn’t make the money available.
They did not refuse—the decision was
deferred until the next financial year.”
Systems for
managing
guidance
Robust Regular reports on compliance to
Clinical Governance Committee.
Adequate staffing of clinical
governance function
“We have a 10 stage implementation
model that seems to work very well.”
No tracking
Small trusts with limited
resources in clinical
governance function
“Our clinical governance function
consists of the medical director and
one other person plus a couple of part
time audit clerks.”
Proactive Early identification of topics being
considered by NICE
Identification of local implications and
funding requirements
“We proactively hunt out guidance
pertaining to the directorate.
Additionally, there is someone
responsible for NICE guidance
implementation in the clinical
effectiveness department who asks
each department head about the
management of appropriate guidance.”
Guidance dealt with on
publication
“When the guidance comes in we
send it to the appropriate directorate.”
Audited Regular audits of compliance “We have limited resource to audit, so
we’ve tended to audit where we know
we’ve not been complying.”
No audit of compliance “We have been asked whether or not
we comply, but nobody from the
Trust has looked through our records
as far as I am aware.”
Funding Sufficient funding identified for all
revenue consequences including
infrastructure
“Financially we have taken a hard
line—no money no
implementation—on drugs at any
rate.”
Commissioner argument that
money is already in the
baseline
“Because money has not been
hypothecated in the proper fashion,
we end up with arguments between
government regions, strategic health
authorities, primary care trusts, and
ourselves around where the money
sits and we end up with this recurrent
thing, saying it’s in the baseline.”
Consultant buy in Perceived
robustness of
evidence
Guidance consistent with other
sources of evidence, royal college
guidelines, etc
“No different from what we’re already
doing. We’d already looked at it, and I
remember it coming out and
discussing it, and people saying it was
along the same lines as what we’d
already done . . . .”
Local evidence at odds with
NICE assessment.
Belief that the evidence base
does not justify the guidance.
“This area has pioneered laparascopic
surgery, and I think that’s one of the
only NICE guidances where we have
varied from them. We actually wrote
to NICE at the time, stating our
reasons for doing so, on the basis
that we had additional expertise and
there was a deliberate policy decision
taken both within the trust.”
Consultation Contributed to guidance or views
properly represented
“We, particularly in this department,
had a very active role in drawing up
the guidelines . . . way back in the mid
to late 1990s we were already
disseminating guidelines on wisdom
teeth.”
Guidance viewed as biased, or
failing to take key factors into
account
“By and large the perception is that
this particular advice was ‘London
centred,’ and getting NICE to change
their minds is a difficult task.”
Clinical
freedom
Guidance is mandatory “Even though we have not agreed with
advice from NICE either on
laparoscopic hernia repair or
laparoscopic colorectal surgery, there
has been no suggestion locally that
we should ‘plough our own furrow.’”
Guidance is guidance only “I don’t use guidance; I use my own
clinical experience.”
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Unanswered questions and future research
Our research covers the early period of NICE guidance; it would
be interesting to see if the response to subsequent guidance is
different, particularly given the recent attention that NICE is giv-
ing to implementation. More research would also be useful to
understand the professional and organisational responses to evi-
dence based guidance better and to evaluate the relative contri-
butions of various implementation strategies to practice
patterns.17
Conclusions
NICE guidance has been associated with uptake of some
technologies, although this has been variable. Implementation is
likely to be improved if the guidance is clear and based on an
understanding of clinical practice, if the evidence is strong and
relatively stable, if adequate funding is available, and if the guid-
ance is supported and disseminated by professional bodies.
Trusts should institute strong supportive internal systems for
handling guidance and gathering data on implementation.
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What is already known about this topic
Research on the implementation of guideline
implementation has been summarised, but its relevance to
this unique national initiative was unknown
The implementation of NICE guidance has not been
evaluated overall. Previous work has been limited to single
health technologies
What this study adds
Some clinical practice has changed in line with NICE
guidance, in particular around prescribing (for example
taxanes and orlistat)
Other technologies have been adopted in line with NICE
guidance but continued pre-existing practice patterns
There is evidence that NICE guidance has been less
influential in surgical procedures and use of medical
devices
Routine data are not sufficient to assess compliance with
guidance; this needs review of case notes
NICE guidance seems to have had an uneven impact on the
uptake of evidence based medicine. This impact is likely to
be greater if more effort is devoted to clarity of the
guidance and its relevance to practice; adequate funding
provision; getting professional support; and encouraging
healthcare organisations to set up formal mechanisms for
handling guidance
Papers
page 8 of 8 BMJ VOLUME 329 30 OCTOBER 2004 bmj.com
 on 12 November 2004 bmj.comDownloaded from 
